From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible protease-activated receptor-1(PAR1) antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects [1] .
Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor with an EC50 range of 0.1-0.5 μM [1]. Micrococcin P1 has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Micrococcin P1 against S. aureus 1974149, E. faecalis 1674621 and S. pyogenes 1744264 are 2 μg/mL, 1 μg/mL and 1 μg/mL, respectively . Micrococcin P1 is also a potent inhibitor of the malaria parasitePlasmodium falciparum .
Nuclease P1 is a single-stranded specific endonuclease, it hydrolyzes nucleic acids into 5'-mononucleotides and cleaves the single-stranded region of a double-stranded nucleic acid. Nuclease P1 is one of the most well-known single stranded specific nucleases in the field of molecular biology, it is widely used in the pharmaceutical and food industries [1].
Cecropin P1, porcine is an antibacterial peptide that can be isolated from the upper part of the small intestine of the pig. Cecropin P1, porcine shows antibacterial activity against Gram-negative bacteria. Cecropin P1, porcine shows antiviral activity and inhibits PRRSV infection [1] .
P1 is a broad-spectrum antimicrobial peptide. P1 shows antibacterial activity against Gram-positive and Gram-negative bacteria,such as B. anthracis spores and Carbapenem-resistant A. baumannii and K. pneumoniae[1].
Cecropin P1, porcine acetate is an antibacterial peptide that can be isolated from the upper part of the small intestine of the pig. Cecropin P1, porcine acetate shows antibacterial activity against Gram-negative bacteria. Cecropin P1, porcine acetate shows antiviral activity and inhibits PRRSV infection [1] .
THZ-P1-2 is a first-in-class and selective PI5P4K inhibitor, with an IC50 of 190 nM for PI5P4Kα. THZ-P1-2 covalently targets cysteines on a disordered loop in PI5P4Kα/β/γ. THZ-P1-2 causes autophagy disruption and upregulates TFEB signaling. THZ-P1-2 displays anticancer activity in leukemia cell lines [1].
TTA-P1 is a potent state-independent compound inhibiting human T-type calcium channel. T-type calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. TTA-P1 has the potential for the research of absence epilepsy [1].
SZL P1-41 is a specific Skp2 inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities [1] .
PtdIns-(3)-P1(1,2-dioctanoyl) sodium (compound 1b) is a glycogen phosphate that plays a key role in eukaryotic membrane trafficking and agonist-activated intracellular signaling [1].
12-Methyltridecanoic acid is a methylated fatty acid that has been found in milk. 12-Methyltridecanoic acid (200 μM) reduces angiogenesis and corneal opacity in alkaline or Pseudomonas aeruginosa-induced ocular mouse models.
PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis[1] .
PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis[1] .
PDI-IN-1 (Compound P1) is a cell-permeable human protein disulfide isomerase (PDI) inhibitor with an IC50 of 1.7 μM. PDI-IN-1 has anti-cancer activity.
1-(2-Quinoxalinyl)-1,2,3,4-butanetetrol is an endogenous metabolite. The imprinted polymer P-1 shows affinity for 1-(2-Quinoxalinyl)-1,2,3,4-butanetetrol [1].
SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC50 value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole [1].
TLK117, the active metabolite of TLK199, selective inhibits Glutathione S-transferase P1–1(GSTP1-1) with a Ki of 0.4 μM for GSTP. TLK117 also competitively inhibits glyoxalase I with a Ki of 0.56 μM.
Antitubercular agent-39 (Compound P1) is a potent antitubercular agent. Antitubercular agent-39 is active against drug-resistant strains and drug-susceptible clinical isolates. Antitubercular agent-39 inhibits Mtb strain H37Rv with a MIC less than 1 μM [1].
PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha (ERα) degrader.
Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1(GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment [1] .
Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1(GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment [1] .
Canfosfamide (TLK-286, TER286) is a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and induces apoptosis. Canfosfamide also inhibits the catalytic kinase activity of DNA-dependent protein kinase (DNA-PK). Canfosfamide produces an anticancer alkylating agent and a glutathione derivative after activation. Canfosfamide can be used to research malignancies [1] .
NBDHEX is a potent glutathione S-transferase P1-1(GSTP1-1) inhibitor. NBDHEX induces apoptosis of tumor cells. NBDHEX acts as an anticancer agent by inhibiting GSTs catalytic activity, avoiding inconvenience of the inhibitor extrusion from the cell by specific pumps and disrupting the interaction between the GSTP1-1 and key signaling effectors. NBDHEX can also act as late-phase autophagy inhibitor [1] .
alpha-1,4-Galactosyltransferase (LgtC) (A4GALT) is a glycosphingolipid-specific glycosyltransferase. alpha-1,4-Galactosyltransferase (LgtC) transfers a galactose to the alpha-1,4 position of lactosylceramide to form globotriaosylceramide. alpha-1,4-Galactosyltransferase (LgtC) can be used for the synthesis of P1 blood group antigens [1] .
(S,S)-Z-FA-FMK is a cell-permeable, irreversible cathepsin B inhibitor. (S,S)-Z-FA-FMK blocks LPS-induced production of IL-1α and IL-1β. (S,S)-Z-FA-FMK can be used as a negative control for caspase-1 and caspase-2 inhibitors because it lacks an aspartic acid residue at the P1 position [1] .
Substance P(1-7) is a fragment of the neuropeptide, substance P (SP). Substance P(1-7) gives depressor and bradycardic effects when applied to the nucleus tractus solitarius [1].
Substance P(1-7) TFA is a fragment of the neuropeptide, substance P (SP). Substance P(1-7) TFA gives depressor and bradycardic effects when applied to the nucleus tractus solitarius [1].
S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS) [1].
S1P1 agonist 6 (Compound I) is a S1P1 agonist that reduces autoimmune ability by blocking the transportation of lymphocytes. S1P1 agonist 6 can be used as an immunosuppressive agent in the study of various autoimmune diseases research [1].
S1P1 agonist 6 hemicalcium (Compound I) is a S1P1 agonist that reduces autoimmune ability by blocking the transportation of lymphocytes. S1P1 agonist 6 hemicalcium can be used as an immunosuppressive agent in the study of various autoimmune diseases research [1].
Ex26 (S1P1-IN-Ex26) is a potent and selective sphingosine 1-phosphate receptor 1(S1P1) antagonist (IC50=0.93 nM). Ex26 shows >3,000-fold selectivity for S1P1 over other Sphingosine 1-phosphate receptors. Ex26 can be used in experimental autoimmune encephalomyelitis reseach [1].
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC50s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome [1] .
PIP4P1 Human Pre-designed siRNA Set A contains three designed siRNAs for PIP4P1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
CD161 (NKR-P1A) is a potent, selective and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC50s of 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2, respectively. CD161 has good anticancer activity [1].
NIBR-0213 is a potent, orally active and selective S1P1 antagonist with efficacy in experimental autoimmune encephalomyelitis. NIBR-0213 displays potent and comparable potency on human and rat S1P1 (IC50 of 2.0 nM and 2.3 nM, respectively) in GTPγ 35S assays [1].
TPE-1p is a cascade-activated AIEgen-peptide probe. TPE-1p self-assembles in aqueous solution to exhibit bright fluorescence in response to alkaline phosphatase (ALP) and ChT-L. TPE-1p can be utilized to noninvasively assess the inhibition efficiency of a ChT-L inhibitor in cells [1].
Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation [1] .
(E)-3,4-Dimethoxycinnamyl alcohol is an antimutagenic. (E)-3,4-Dimethoxycinnamyl alcohol has antimutagenic activity against furylfuramide, Trp-P-1, and activated Trp-P-1[1].
Galcuronokinase (AtGalAK) is a member of the GHMP kinase family. Galcuronokinase (AtGalAK) catalyzes the ATP-dependent conversion of alpha-d-galacturonic acid (d-GalA) to alpha-d-galacturonic acid-1-phosphate (GalA-1-P) .
Ponesimod-d4 (ACT-128800-d4)is the deuterium labeledPonesimod(HY-10569) [1]. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .
N-Acetylhexosamine kinase (NahK) is an anomeric kinase acting on a glucose-type substrate. N-Acetylhexosamine kinase catalyzes the phosphorylation of GlcNAc or GalNAc at the anomeric C1 position with ATP to form N-acetylhexosamine 1-phosphate (GlcNAc-1P/GalNAc-1P) .
Ponesimod-d7 (ACT-128800-d7) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d7 (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod-d7 activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod-d7 can protect against lymphocyte-mediated tissue inflammation [1] .
trans-Coniferyl aldehyde (compound 2) is a natural compound isolated from the buds of clove (Syzygium aromaticum).trans-Coniferyl aldehyde suppresses 63% of the UV mutable gene expression at 1.20 μM, and with an ID50 value of 0.76 μM,and has the antimutagenic
activities against furylfuramide, Trp-P-1, and activated Trp-P-1[1].
CYM5442 hydrochloride is a potent, highly-selective and orally active sphingosine 1-phosphate (S1P1) receptor agonist with an EC50 of 1.35 nM. CYM5442 hydrochloride is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 hydrochloride activates S1P1-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 hydrochloride can easily penetrate the central nervous system (CNS) [1] .
CYM5442 is a potent, highly-selective and orally active sphingosine 1-phosphate (S1P1) receptor agonist with an EC50 of 1.35 nM. CYM5442 is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 activates S1P1-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 can easily penetrate the central nervous system (CNS) [1] .
CS-2100 (Compound 10b) is a potent, selective, orally active and S1P3-sparingS1P1 agonist with an EC50 of 4.0 nM for human S1P1. CS-2100 shows in vivo immunosuppressive efficacy in rats with an ID50 (infective dose) of 0.407 mg/kg for HvGR [1].
SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses [1] .
RP-001 is a picomolar short-acting S1P1(EDG1) selective agonist, with an EC50 of 9 pM. RP-00 induces internalization and polyubiquitination of S1P1. RP-001 has little activity on S1P2-S1P4 and only moderate affinity for S1P5 [1].
RP-001 hydrochloride is a picomolar short-acting S1P1(EDG1) selective agonist, with an EC50 of 9 pM. RP-00 hydrochloride induces internalization and polyubiquitination of S1P1. RP-001 hydrochloride has little activity on S1P2-S1P4 and only moderate affinity for S1P5 [1].
Udifitimod (BMS-986166) is a potent, selective and orally active S1P1R modulator. Udifitimod has the potential for the research of autoimmune diseases [1] .
Ozanimod (RPC-1063), a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) [1].
Ozanimod (RPC-1063) hydrochloride, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod hydrochloride has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod hydrochloride can be used for the research of relapsing multiple sclerosis (MS) [1].
Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1(S1P1) receptor with an IC50 value of 1.88 nM in CHO cells.
Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.
CYM50260 is a potent and exquisitely selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonist with an EC50 of 45 nM. CYM50260 displays no activity against S1P1-R,S1P2-R,S1P3-R and S1P5-R[1].
Cenerimod (ACT-334441) is a potent, selective and orally active S1P1 receptor modulator, with an EC50 of 1 nM. Cenerimod shows more than 36 fold selctivity for hS1P1 over hS1P2, hS1P3, hS1P4, and hS1P5 receptor subtypes (EC50s=>10000, 228, 2134, and 36 nM, respectively). Cenerimod can attenuate murine experimental autoimmune encephalomyelitis (EAE) and murine sclerodermatous [1] .
BI01826025 (pArg-JQ1) is a bromodomain1 of BRDT (BRDTBD1) PROTAC degrader. BI01826025 can be used for testing the regulatory effect of ClpC2 on the ClpC1P1P2 protease [1].
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile [1].
ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile [1].
GlcNAc kinase (EcNagK) (N-Acetylglucosamine kinase) is a GlcNAc-metabolizing enzyme. GlcNAc kinase (EcNagK) transfers the gamma-phosphoryl group of an ATP onto the hydroxyl group at the C-6 of GlcNAc to generate a GlcNAc-6-P .
ACT-209905 is a S1P1 receptor agonist. ACT-209905 can inhibit glioblastoma (GBM) cell growth and migration. ACT-209905 also has immunomodulating activity, and can be used in research of autoimmune diseases [1].
W123, a FTY720 analog, is a competitive sphingosine 1-phosphate type 1 (S1P1) receptor antagonist. W123 is measured by GTPγS activation, MAPK recruitment, cell migration, and ligand-induced receptor internalization [1].
RIP1 kinase inhibitor 6 is a potent and selective RIP1 kinase inhibitor with an IC50 of < 100 nM in human R1P1 kinase assay. RIP1 kinase inhibitor 6 is extracted from patent WO2020103884, example 80 [1].
GDP-α-D-mannose disodium is the donor substrate for mannosyltransferases and the precursor of GDP-β-L-fucose. GDP-α-D-mannose disodium gives a competitive inhibition with respect to GTP (Ki 14.7 μM) and an uncompetitive inhibition with respect to mannose-1-P (Ki 115 μM) [1].
GDP-α-D-mannose disodium is the donor substrate for mannosyltransferases and the precursor of GDP-β-L-fucose. GDP-α-D-mannose disodium gives a competitive inhibition with respect to GTP (Ki 14.7 μM) and an uncompetitive inhibition with respect to mannose-1-P (Ki 115 μM) [1].
CYM50308 (ML248) is a potent, selective and high affinity sphingosine-1-phosphate receptor 4 (S1P4-R) agonist with an EC50 of 56 nM. CYM50308 displays 37-fold more selective for S1P4-R than S1P5-R. CYM50308 has no activity at S1P1-R,S1P2-R and S1P3-R subtypes at concentrations up to 25 μM [1].
N-acetyl-α-d-glucosamine 1-phosphate disodium (GlcNAc-1-P), an anomeric sugar phosphate, is a key intermediate in the biosynthesis of N-linked glycoproteins. N-acetyl-α-d-glucosamine 1-phosphate disodium is a metabolic precursor of the bacterial cell-wall components teichoic acid and mureine [1].
SRG-II-19F (dCym-JQ1) is a bromodomain1 of BRDT (BRDTBD1)PROTAC degrader. SRG-II-19F can be used for testing the regulatory effect of ClpC2 on the ClpC1P1P2 protease [1].
UDP-sugar pyrophosphorylase (BlUSP) is the enzyme capable of activating glucose-1-phosphate (Glc-1-P) to UDP-glucose (UDP-Glc). UDP-sugar pyrophosphorylase (BlUSP) catalyzes a reversible transfer of the uridyl group from UTP to sugar-1-phosphate, producing UDP-sugar and pyrophosphate (PPi) [1].
GlcNAc 1-P uridyltransferase (CjGlmU) is a sugar nucleotidyltransferase (SNT). GlcNAc 1-P uridyltransferase (CjGlmU) utilizes UTP and GlcNAc-1-P as its natural substrates, synthesizes UDP-GlcNAc. GlcNAc 1-P uridyltransferase (CjGlmU) has the potential for the research of antimicrobial agents [1].
GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC50s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.
TASP0277308 is a highly selective S1P1 antagonist. TASP0277308 possesses immunomodulatory activities, including lymphopenia, a block in T cell egress from the thymus, marginal zone B cell displacement, and the upregulation of CD69 expression on lymphocytes. TASP0277308 can be used for the research of collagen-induced arthritis in mice [1].
TC-SP 14 (compound 14) is an orally active and potent S1P1 agonist (EC50 = 0.042 μM) with minimal activity at S1P3 (EC50 = 3.47 μM). TC-SP 14 significantly reduces blood lymphocyte counts and attenuates a delayed type hypersensitivity (DTH) response to antigen challenge [1].
Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.
VPC 23019, an aryl amide-containing Sphingosine 1-phosphate (S1P) analog, is a competitive antagonist at the S1P1 and S1P3 receptors (pKi= 7.86 and 5.93, respectively) and an agonist at the S1P4 and S1P5 receptors (pEC50= 6.58 and 7.07, respectively) [1].
Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate(S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator [1] .
L-threo Lysosphingomyelin (d18:1) (L-threo-Sphingosylphosphorylcholine) is an endogenous bioactive sphingolipid. L-threo Lysosphingomyelin (d18:1) is a potent S1P receptor agonist with EC50s of 19.3, 131.8, and 313.3 nM for hS1P1,hS1P3, and hS1P2, respectively [1].
S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the S1P1 and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders [1].
N-acetylglucosamine-1-P uridyltransferase (AGX1) (EC 2.3.1.157) (GlcNAc1pUT) is a bifunctional acetyltransferase/uridyltransferase. N-acetylglucosamine-1-P uridyltransferase (AGX1) binds GlcNAc-1-P and UTP, and catalyzes an uridyltransfer reaction to synthesize UDP-GlcNAc. N-acetylglucosamine-1-P uridyltransferase (AGX1) is a bifunctional enzyme exclusive to prokaryotes [1].
NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1(PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p .
Siponimod (BAF-312) is an orally active and selective sphingosine-1-phosphate(S1P) receptor modulator. Siponimod is selective for S1P1 and S1P5 over S1P2,S1P3, and S1P4, with EC50s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research [1]- .
ASP1126 is a selective and orally active sphingosine-1-phosphate (S1P) agonist, with EC50 values of 7.12 nM, 517 nM for hS1P1 and hS1P3, respectively. ASP1126 decreases the number of peripheral lymphocytes, naive T cells, central memory T cells and effector memory T cells in the peripheral blood. ASP1126 has the potential to be applied in clinical transplantation with improved safety profile [1].
IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research [1] .
D-galactosyl-β1-3-N-acetyl-D-hexosamine phosphorylase (BiGalHexNAcP) is a member of CAZy glycoside hydrolase GH112 family, is often used in biochemical studies. D-galactosyl-β1-3-N-acetyl-D-hexosamine phosphorylase (BiGalHexNAcP) catalyses the phosphorolysis of lacto-n-biose and galacto-n-biose, to produce Gal-1-P and the corresponding N-acetyl-D-hexosamine [1].
Fingolimod (hydrochloride) (Standard) is the analytical standard of Fingolimod (hydrochloride). This product is intended for research and analytical applications. Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate(S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator [1] .
Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca 2+ as an extracellular ligand for G protein-coupled receptors [1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids .
Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research [1] .
A-971432 is a potent, selective and orally active sphingosine-1-phosphate (S1P) receptor 5 agonist with IC50s of .362, >10, 0.006 µM for S1P1, S1P3, S1P5 respectively. A-971432 protects blood–brain barrier (BBB) homeostasis. A-971432 reverses age-related cognitive decline. A-971432 has the potential for the research of alzheimer’s disease or multiple sclerosis [1] .
Siponimod-d11 is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P1 and S1P5 over S1P2, S1P3, and S1P4, with EC50s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research [1] .
Sphingosine-1-phosphate-d7 is the deuterium labeled Sphingosine-1-phosphate. Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca2+ as an extracellular ligand for G protein-coupled receptors[1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids[2].
Nuclease P1 is a single-stranded specific endonuclease, it hydrolyzes nucleic acids into 5'-mononucleotides and cleaves the single-stranded region of a double-stranded nucleic acid. Nuclease P1 is one of the most well-known single stranded specific nucleases in the field of molecular biology, it is widely used in the pharmaceutical and food industries [1].
12-Methyltridecanoic acid is a methylated fatty acid that has been found in milk. 12-Methyltridecanoic acid (200 μM) reduces angiogenesis and corneal opacity in alkaline or Pseudomonas aeruginosa-induced ocular mouse models.
Galcuronokinase (AtGalAK) is a member of the GHMP kinase family. Galcuronokinase (AtGalAK) catalyzes the ATP-dependent conversion of alpha-d-galacturonic acid (d-GalA) to alpha-d-galacturonic acid-1-phosphate (GalA-1-P) .
N-Acetylhexosamine kinase (NahK) is an anomeric kinase acting on a glucose-type substrate. N-Acetylhexosamine kinase catalyzes the phosphorylation of GlcNAc or GalNAc at the anomeric C1 position with ATP to form N-acetylhexosamine 1-phosphate (GlcNAc-1P/GalNAc-1P) .
GlcNAc kinase (EcNagK) (N-Acetylglucosamine kinase) is a GlcNAc-metabolizing enzyme. GlcNAc kinase (EcNagK) transfers the gamma-phosphoryl group of an ATP onto the hydroxyl group at the C-6 of GlcNAc to generate a GlcNAc-6-P .
UDP-sugar pyrophosphorylase (BlUSP) is the enzyme capable of activating glucose-1-phosphate (Glc-1-P) to UDP-glucose (UDP-Glc). UDP-sugar pyrophosphorylase (BlUSP) catalyzes a reversible transfer of the uridyl group from UTP to sugar-1-phosphate, producing UDP-sugar and pyrophosphate (PPi) [1].
GlcNAc 1-P uridyltransferase (CjGlmU) is a sugar nucleotidyltransferase (SNT). GlcNAc 1-P uridyltransferase (CjGlmU) utilizes UTP and GlcNAc-1-P as its natural substrates, synthesizes UDP-GlcNAc. GlcNAc 1-P uridyltransferase (CjGlmU) has the potential for the research of antimicrobial agents [1].
GlcNAc 1-P uridyltransferase (PmGlmU) catalyzes high efficient synthesis of UDP-GlcNAc from GlcNAc-1-P and UTP. GlcNAc 1-P uridyltransferase (PmGlmU) is used to break down the pyrophosphate formed in the PmGlmU reaction to inorganic phosphate to shift the equilibrium of the coupled enzymatic reactions towards the formation of UDP-GlcNA [1].
D-galactosyl-β1-3-N-acetyl-D-hexosamine phosphorylase (BiGalHexNAcP) is a member of CAZy glycoside hydrolase GH112 family, is often used in biochemical studies. D-galactosyl-β1-3-N-acetyl-D-hexosamine phosphorylase (BiGalHexNAcP) catalyses the phosphorolysis of lacto-n-biose and galacto-n-biose, to produce Gal-1-P and the corresponding N-acetyl-D-hexosamine [1].
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible protease-activated receptor-1(PAR1) antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects [1] .
Cecropin P1, porcine is an antibacterial peptide that can be isolated from the upper part of the small intestine of the pig. Cecropin P1, porcine shows antibacterial activity against Gram-negative bacteria. Cecropin P1, porcine shows antiviral activity and inhibits PRRSV infection [1] .
P1 is a broad-spectrum antimicrobial peptide. P1 shows antibacterial activity against Gram-positive and Gram-negative bacteria,such as B. anthracis spores and Carbapenem-resistant A. baumannii and K. pneumoniae[1].
Cecropin P1, porcine acetate is an antibacterial peptide that can be isolated from the upper part of the small intestine of the pig. Cecropin P1, porcine acetate shows antibacterial activity against Gram-negative bacteria. Cecropin P1, porcine acetate shows antiviral activity and inhibits PRRSV infection [1] .
PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis[1] .
PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis[1] .
TLK117, the active metabolite of TLK199, selective inhibits Glutathione S-transferase P1–1(GSTP1-1) with a Ki of 0.4 μM for GSTP. TLK117 also competitively inhibits glyoxalase I with a Ki of 0.56 μM.
Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-(COO)Ala-Ser-Lys(DABCYL)-NH2 (HCV NS3 protease substrate) is a biological active peptide. (This peptide is a HCV protease substrate incorporating an ester bond between residues P1 and P1. Due to ready transesterification of the scissile bond to the acyl-enzyme intermediate, this substrate shows very high kcat/Km values, enabling detection of activity with subnanomolar nonstructural protein 3 (NS3 protease) concentrations. It is widely used for the continuous assay of NS3 protease activity. Substrate cleavage is proportional to the enzyme concentration with a detection limit for NS3 between 1 nM and 250 pM. Upon cleavage of this substrate, fluorescence can be monitored at Abs/Em = 355/500 nm.)
Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1(GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment [1] .
Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1(GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment [1] .
Substance P(1-7) is a fragment of the neuropeptide, substance P (SP). Substance P(1-7) gives depressor and bradycardic effects when applied to the nucleus tractus solitarius [1].
Substance P(1-4) is a potent neurokinin receptors (NK-R) antagonist. Substance P(1-4) has regulation of normal hematopoiesis and inhibits endogenous erythroid colony (EEC) formation [1].
Substance P(1-7) TFA is a fragment of the neuropeptide, substance P (SP). Substance P(1-7) TFA gives depressor and bradycardic effects when applied to the nucleus tractus solitarius [1].
GDP-α-D-mannose disodium is the donor substrate for mannosyltransferases and the precursor of GDP-β-L-fucose. GDP-α-D-mannose disodium gives a competitive inhibition with respect to GTP (Ki 14.7 μM) and an uncompetitive inhibition with respect to mannose-1-P (Ki 115 μM) [1].
1-(2-Quinoxalinyl)-1,2,3,4-butanetetrol is an endogenous metabolite. The imprinted polymer P-1 shows affinity for 1-(2-Quinoxalinyl)-1,2,3,4-butanetetrol [1].
trans-Coniferyl aldehyde (compound 2) is a natural compound isolated from the buds of clove (Syzygium aromaticum).trans-Coniferyl aldehyde suppresses 63% of the UV mutable gene expression at 1.20 μM, and with an ID50 value of 0.76 μM,and has the antimutagenic
activities against furylfuramide, Trp-P-1, and activated Trp-P-1[1].
GDP-α-D-mannose disodium is the donor substrate for mannosyltransferases and the precursor of GDP-β-L-fucose. GDP-α-D-mannose disodium gives a competitive inhibition with respect to GTP (Ki 14.7 μM) and an uncompetitive inhibition with respect to mannose-1-P (Ki 115 μM) [1].
N-acetyl-α-d-glucosamine 1-phosphate disodium (GlcNAc-1-P), an anomeric sugar phosphate, is a key intermediate in the biosynthesis of N-linked glycoproteins. N-acetyl-α-d-glucosamine 1-phosphate disodium is a metabolic precursor of the bacterial cell-wall components teichoic acid and mureine [1].
Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca 2+ as an extracellular ligand for G protein-coupled receptors [1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids .
TFF3 Protein is crucial for maintaining and repairing the intestinal mucosa, promoting epithelial cell mobility as a motogen. As a monomer, TFF3 has individual effects, while as a disulfide-linked homodimer, it enhances cellular responses for intestinal lining integrity. TFF3's multifaceted nature underscores its significance in balancing mucosal maintenance and repair in the gastrointestinal tract. TFF3 Protein, Human (P. pastoris, His) is the recombinant human-derived TFF3 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of TFF3 Protein, Human (P. pastoris, His) is 52 a.a., with molecular weight of 7.5 kDa.
TFF3 Protein intricately maintains and repairs the intestinal mucosa, acting as a motogen that promotes epithelial cell mobility during healing. Existing as a monomer, TFF3 can form homodimers through disulfide linkages, suggesting a role in mediating crucial interactions. Its involvement in mucosal repair underscores TFF3's significance in dynamic processes that preserve the integrity and functionality of the intestinal lining. TFF3 Protein, Canine (HEK293, His) is the recombinant canine-derived TFF3 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of TFF3 Protein, Canine (HEK293, His) is 57 a.a., with molecular weight of 9.2 kDa.
The EIF2AK2 protein is an interferon-inducing kinase that initiates the innate immune response against viral infection. It phosphorylates eIF-2-α, activating the integrated stress response, inhibiting overall protein synthesis and favoring ISR-specific mRNAs such as ATF4. EIF2AK2 Protein, Human (P. pastoris, His) is the recombinant human-derived EIF2AK2 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of EIF2AK2 Protein, Human (P. pastoris, His) is 550 a.a., with molecular weight of 64 kDa.
Aminopeptidase P1 Protein, Human (His) is a recombinant human Aminopeptidase P1 with a His tag at the C-terminus. Aminopeptidase P1 belongs to a family of aminopeptidase Ps (aminopeptidases P1-3 encoded by the Xpnpep1-3 genes) that cleave the N-terminal amino acid residue of peptides in which the penultimate amino acid is proline.
The RPLP1 protein plays a critical role in the fundamental cellular process of elongation of protein synthesis. It binds to RPLP2 and forms a heterodimer on the ribosome side stalk, positioning RPLP1 as a component of the ribosomal machinery. RPLP1 Protein, Human (sf9, His) is the recombinant human-derived RPLP1 protein, expressed by Sf9 insect cells , with N-His labeled tag. The total length of RPLP1 Protein, Human (sf9, His) is 114 a.a., with molecular weight of ~13.8 kDa.
Aminopeptidase P1 Protein, a metalloaminopeptidase, crucially catalyzes the removal of penultimate prolyl residues from peptide N-termini, including substrates like Arg-Pro-Pro. This activity significantly contributes to specific peptide degradation, exemplified in bradykinin processing. Aminopeptidase P1's selective prolyl cleavage underscores its importance in modulating peptide structures and functions within biological systems. Aminopeptidase P1 Protein, Human (His-SUMO) is the recombinant human-derived Aminopeptidase P1 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of Aminopeptidase P1 Protein, Human (His-SUMO) is 622 a.a., with molecular weight of ~85.8 kDa.
CD161 Protein plays a crucial role in inhibiting NK cell cytotoxicity by activating specific acid sphingomyelinase/SMPD1, elevating ceramide levels. Activation stimulates AKT1/PKB and RPS6KA1/RSK1 kinases, enhancing anti-CD3-induced T-cell proliferation. As a lectin, CD161 binds to Gal-alpha(1,3)Gal and N-acetyllactosamine epitopes, acting as a ligand for CLEC2D/LLT1. Existing as a homodimer, CD161 interacts with acid sphingomyelinase/SMPD1, contributing to its multifaceted immune regulatory functions. CD161 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD161 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD161 Protein, Cynomolgus (HEK293, His) is 161 a.a., with molecular weight of 38-48 kDa.
CD161 Protein plays a crucial role in inhibiting NK cell cytotoxicity by activating specific acid sphingomyelinase/SMPD1, elevating ceramide levels. Activation stimulates AKT1/PKB and RPS6KA1/RSK1 kinases, enhancing anti-CD3-induced T-cell proliferation. As a lectin, CD161 binds to Gal-alpha(1,3)Gal and N-acetyllactosamine epitopes, acting as a ligand for CLEC2D/LLT1. Existing as a homodimer, CD161 interacts with acid sphingomyelinase/SMPD1, contributing to its multifaceted immune regulatory functions. CD161 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is the recombinant cynomolgus-derived CD161 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of CD161 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is 161 a.a., with molecular weight of 37-42 kDa.
CD161 protein plays a crucial role in inhibiting NK cell toxicity by activating specific acid sphingomyelinase/SMPD1 and increasing ceramide levels. Activation stimulates AKT1/PKB and RPS6KA1/RSK1 kinases, enhancing anti-CD3-induced T cell proliferation. CD161 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD161 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of CD161 Protein, Human (Biotinylated, HEK293, His-Avi) is 159 a.a., with molecular weight of 35-43 kDa.
CL-P1/COLEC12 is a multifunctional scavenger receptor that effectively defends against microorganisms and promotes their binding and phagocytosis, covering Gram-positive and Gram-negative bacteria and yeast. In addition, it mediates the recognition, internalization, and degradation of oxidatively modified low-density lipoprotein (oxLDL) by vascular endothelial cells. CL-P1/COLEC12 Protein, Rat (sf9, His) is the recombinant rat-derived CL-P1/COLEC12 protein, expressed by Sf9 insect cells , with N-His labeled tag. The total length of CL-P1/COLEC12 Protein, Rat (sf9, His) is 642 a.a., with molecular weight of ~90 KDa.
Collectin-12 is a family of Ca2+-dependent, C-type lectins that contain a collagenous domain and function as recognition molecules for molecular patterns found on pathogens (1 - 4). CL-P1/COLEC12 Protein, Rhesus Macaque (sf9, His) is the recombinant Rhesus Macaque-derived CL-P1/COLEC12 protein, expressed by Sf9 insect cells , with N-His labeled tag. The total length of CL-P1/COLEC12 Protein, Rhesus Macaque (sf9, His) is 642 a.a., with molecular weight of ~72.3 KDa.
MASP2 Protein exhibits a deficiency in conserved residue(s) crucial for feature annotation propagation. MASP2 Protein, Cynomolgus (His) is the recombinant cynomolgus-derived MASP2 protein, expressed by E. coli , with C-His labeled tag. The total length of MASP2 Protein, Cynomolgus (His) is 400 a.a., with molecular weight of 21-24 kDa.
MASP2 Protein, a serum protease, plays a pivotal role in activating the complement system by cleaving C2 and C4 upon auto-catalytic cleavage. This activation leads to the formation of C3 convertase, a crucial step in initiating the complement cascade through mannose-binding lectin. MASP2 Protein, Mouse (His) is the recombinant mouse-derived MASP2 protein, expressed by E. coli , with C-His labeled tag. The total length of MASP2 Protein, Mouse (His) is 399 a.a., with molecular weight of 18-20 kDa.
Mannan-binding lectin serine protease 2 (MASP2) is a protein defective in conserved residues required for propagation of signature annotations. Specific residues missing in MASP2 prevent the propagation of certain functional features associated with this protein. MASP2 Protein, Rat (His) is the recombinant rat-derived MASP2 protein, expressed by E. coli , with C-His labeled tag. The total length of MASP2 Protein, Rat (His) is 399 a.a., with molecular weight of 15-20 kDa.
MASP2 Protein, a serum protease, critically activates the complement system by auto-catalytically cleaving and subsequently cleaving C2 and C4. This process leads to the activation of C3 and the formation of C3 convertase, essential for the complement cascade. MASP2 Protein, Human (His) is the recombinant human-derived MASP2 protein, expressed by E. coli , with C-His labeled tag. The total length of MASP2 Protein, Human (His) is 399 a.a., with molecular weight of 18 kDa & 25-30 kDa, respectively.
Mannan-binding lectin serine protease 2 (MASP2) is a protein defective in conserved residues required for propagation of signature annotations. Specific residues missing in MASP2 prevent the propagation of certain functional features associated with this protein. MASP2 Protein, Rat (Biotinylated, His) is the recombinant rat-derived MASP2 protein, expressed by E. coli , with C-His labeled tag. The total length of MASP2 Protein, Rat (Biotinylated, His) is 399 a.a., with molecular weight of 15-20 kDa.
Prostaglandin F2 receptor inhibitor (PTGFRN) is a type I transmembrane Ig superfamily cell adhesion molecule. PTGFRN is overexpressed in glioblastoma and promotes cell growth and radiation resistance through the PI3K-AKT signaling pathway. PTGFRN is involved in adipocyte maturation, muscle regeneration, tumor angiogenesis, metastasis, inhibition of follicle-stimulating hormone and luteinizing hormone secretion, and plasmodium infection. FPRP/PTGFRN Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived FPRP/PTGFRN protein, expressed by HEK293 , with C-His labeled tag. The total length of FPRP/PTGFRN Protein, Cynomolgus (HEK293, His) is 809 a.a., with molecular weight of 96-106 kDa.
TPM4 protein, binding actin filaments in muscle and non-muscle cells, crucially regulates calcium-dependent muscle contraction, aided by the troponin complex in vertebrates. In smooth muscle cells, TPM4 interacts with caldesmon, contributing to contraction regulation. In non-muscle cells, it stabilizes actin filaments in the cytoskeleton. TPM4's calcium-binding ability, homodimer, and heterodimer formation (with alpha and beta chains) showcase its versatile molecular configurations. TPM4's multifaceted interactions emphasize its essential roles in muscle contraction and cytoskeletal dynamics across diverse cellular contexts. TPM4 Protein, Human (HEK293, His) is the recombinant human-derived TPM4 protein, expressed by HEK293, with N-His, N-6*His labeled tag. The total length of TPM4 Protein, Human (HEK293, His) is 247 a.a., with molecular weight of 35-40 kDa.
TPBG/5T4 protein acts as an inhibitor of Wnt/β-catenin signaling, possibly by interacting indirectly with LRP6 and hindering Wnt3a-dependent LRP6 internalization. This means that TPBG/5T4 plays a crucial role in regulating the complex Wnt/β-catenin signaling pathway and exerts a regulatory influence on cellular responses related to this pathway. TPBG/5T4 Protein, Human (HEK293, mFc) is the recombinant human-derived TPBG/5T4 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of TPBG/5T4 Protein, Human (HEK293, mFc) is 324 a.a., with molecular weight of 80-110 kDa.
TPBG/5T4 protein acts as an inhibitor of Wnt/β-catenin signaling, possibly by interacting indirectly with LRP6 and hindering Wnt3a-dependent LRP6 internalization. This means that TPBG/5T4 plays a crucial role in regulating the complex Wnt/β-catenin signaling pathway and exerts a regulatory influence on cellular responses related to this pathway. TPBG/5T4 Protein, Human (HEK293, hFc) is the recombinant human-derived TPBG/5T4 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TPBG/5T4 Protein, Human (HEK293, hFc) is 324 a.a., with molecular weight of 75-105 kDa.
TPBG/5T4 protein acts as an inhibitor of Wnt/β-catenin signaling, possibly by interacting indirectly with LRP6 and hindering Wnt3a-dependent LRP6 internalization. This means that TPBG/5T4 plays a crucial role in regulating the complex Wnt/β-catenin signaling pathway and exerts a regulatory influence on cellular responses related to this pathway. TPBG/5T4 Protein, Human (HEK293, Avi-His) is the recombinant human-derived TPBG/5T4 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of TPBG/5T4 Protein, Human (HEK293, Avi-His) is 324 a.a., with molecular weight of 60-90 kDa.
TPBG/5T4 protein acts as an inhibitor of Wnt/β-catenin signaling, possibly by interacting indirectly with LRP6 and hindering Wnt3a-dependent LRP6 internalization. This means that TPBG/5T4 plays a crucial role in regulating the complex Wnt/β-catenin signaling pathway and exerts a regulatory influence on cellular responses related to this pathway. TPBG/5T4 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived TPBG/5T4 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of TPBG/5T4 Protein, Human (Biotinylated, HEK293, His-Avi) is 324 a.a., with molecular weight of 50-70 kDa.
TPBG/5T4 protein acts as an inhibitor of Wnt/β-catenin signaling, possibly by interacting indirectly with LRP6 and hindering Wnt3a-dependent LRP6 internalization. This means that TPBG/5T4 plays a crucial role in regulating the complex Wnt/β-catenin signaling pathway and exerts a regulatory influence on cellular responses related to this pathway. TPBG/5T4 Protein, Human (FITC, HEK293, His-Avi) is the recombinant human-derived TPBG/5T4 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of TPBG/5T4 Protein, Human (FITC, HEK293, His-Avi) is 324 a.a., with molecular weight of 50-70 kDa.
The Klrb1a protein is critical for stimulating NK cell cytotoxicity and contributes to immune defense mechanisms. Klrb1a exists as a homodimer with disulfide bonds and complexly regulates NK cell activity. Klrb1a Protein, Mouse (HEK293, His) is the recombinant mouse-derived Klrb1a protein, expressed by HEK293 , with N-His labeled tag. The total length of Klrb1a Protein, Mouse (HEK293, His) is 161 a.a., with molecular weight of 30-35 kDa.
CD161 protein plays a crucial role in inhibiting NK cell toxicity by activating specific acid sphingomyelinase/SMPD1 and increasing ceramide levels. Activation stimulates AKT1/PKB and RPS6KA1/RSK1 kinases, enhancing anti-CD3-induced T cell proliferation. CD161 Protein, Human (HEK293, Fc) is the recombinant human-derived CD161 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD161 Protein, Human (HEK293, Fc) is 159 a.a., with molecular weight of 55-70 kDa.
TPBG/5T4 protein acts as an inhibitor of Wnt/β-catenin signaling, possibly by interacting indirectly with LRP6 and hindering Wnt3a-dependent LRP6 internalization. This means that TPBG/5T4 plays a crucial role in regulating the complex Wnt/β-catenin signaling pathway and exerts a regulatory influence on cellular responses related to this pathway. TPBG/5T4 Protein, Human (HEK293, His) is the recombinant human-derived TPBG/5T4 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TPBG/5T4 Protein, Human (HEK293, His) is 324 a.a., with molecular weight of 55-80 kDa.
TFF1 protein functions as a mucous gel stabilizer, vital for fortifying the gastrointestinal mucosa against noxious agents. It contributes to the mucous layer's integrity, providing a crucial physical barrier for the gastrointestinal tract, safeguarding it from potential harm. TFF1's stabilizing role emphasizes its significance in preserving the mucosal barrier, essential for overall gastrointestinal health and protection. TFF1 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived TFF1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TFF1 Protein, Mouse (HEK293, Fc) is 66 a.a., with molecular weight of 38-42 kDa.
TFF1 protein acts as an endogenous repressor of isoform 1 and interacts with CHK1, antagonizing its function and promoting the transition from the S to G2/M phase of the cell cycle. TFF1 Protein, Human (HEK293, His) is the recombinant human-derived TFF1 protein, expressed by HEK293, with C-6*His labeled tag. The total length of TFF1 Protein, Human (HEK293, His) is 60 a.a., with molecular weight of ~8.1 kDa.
TPBG/5T4 protein blocks Wnt3a-dependent LRP6 internalization by indirectly interacting with LRP6, thereby potentially inhibiting Wnt/β-catenin signaling. This unique mechanism suggests that TPBG/5T4 plays a crucial role in regulating the Wnt/β-catenin pathway by disrupting LRP6 internalization and affecting downstream signaling. TPBG/5T4 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TPBG/5T4 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TPBG/5T4 Protein, Cynomolgus (HEK293, His) is 321 a.a., with molecular weight of 55-80 kDa.
TPBG/5T4 protein acts as an inhibitor of Wnt/β-catenin signaling, possibly by interacting indirectly with LRP6 and hindering Wnt3a-dependent LRP6 internalization. This suggests that TPBG/5T4 plays a key role in regulating the complex Wnt/β-catenin signaling pathway and influencing cellular responses related to this pathway. TPBG/5T4 Protein, Mouse (HEK293, His) is the recombinant mouse-derived TPBG/5T4 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TPBG/5T4 Protein, Mouse (HEK293, His) is 330 a.a., with molecular weight of 50-70 kDa.
TPBG/5T4 protein blocks Wnt3a-dependent LRP6 internalization by indirectly interacting with LRP6, thereby potentially inhibiting Wnt/β-catenin signaling. This unique mechanism suggests that TPBG/5T4 plays a crucial role in regulating the Wnt/β-catenin pathway by disrupting LRP6 internalization and affecting downstream signaling. TPBG/5T4 Protein, Cynomolgus (HEK293, N-His, C-Myc) is the recombinant cynomolgus-derived TPBG/5T4 protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of TPBG/5T4 Protein, Cynomolgus (HEK293, N-His, C-Myc) is 321 a.a., with molecular weight of 39.9 kDa.
FPRP/PTGFRN protein plays a key role in regulating prostaglandin F2-α (PGF2-α) signaling by inhibiting the binding of PGF2-α to its FP receptor. This inhibition reduces receptor number without changing the affinity constant, revealing subtle mechanisms. FPRP/PTGFRN Protein, Human (HEK293, His) is the recombinant human-derived FPRP/PTGFRN protein, expressed by HEK293 , with C-His labeled tag. The total length of FPRP/PTGFRN Protein, Human (HEK293, His) is 807 a.a., with molecular weight of 100-110 kDa.
The FPRP/PTGFRN Protein inhibits PGF2-alpha binding to its FP receptor, mainly by reducing receptor numbers. It interacts with CD9 and CD81, preventing myotube fusion in myoblasts during muscle regeneration. It also forms a complex with CD9, CD81, and IGSF8, potentially interacting with other tetraspanins like CD63, CD82, and CD151. These interactions highlight its regulatory role in prostaglandin signaling and muscle regeneration. FPRP/PTGFRN Protein, Mouse (HEK293, His) is the recombinant mouse-derived FPRP/PTGFRN protein, expressed by HEK293 , with C-His labeled tag. The total length of FPRP/PTGFRN Protein, Mouse (HEK293, His) is 811 a.a., with molecular weight of 110-120 kDa.
GOLM1 Protein, amid partial comprehension, acts as a cellular response protein to viral infections, with an intricate role yet to be fully understood. Interactions with DYM suggest potential links to cellular dynamics or host-virus interactions. Further investigation is crucial to delineate GOLM1's specific contributions and implications in cellular defense mechanisms against viral infections. GOLM1 Protein, Human (His) is the recombinant human-derived GOLM1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of GOLM1 Protein, Human (His) is 366 a.a., with molecular weight of ~45.6 kDa.
GOLM1 Protein, amid partial comprehension, acts as a cellular response protein to viral infections, with an intricate role yet to be fully understood. Interactions with DYM suggest potential links to cellular dynamics or host-virus interactions. Further investigation is crucial to delineate GOLM1's specific contributions and implications in cellular defense mechanisms against viral infections. GOLM1 Protein, Human (His, Solution) is the recombinant human-derived GOLM1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of GOLM1 Protein, Human (His, Solution) is 366 a.a., with molecular weight of ~60 kDa.
Ponesimod-d7 (ACT-128800-d7) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d7 (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod-d7 activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod-d7 can protect against lymphocyte-mediated tissue inflammation [1] .
Ponesimod-d4 (ACT-128800-d4)is the deuterium labeledPonesimod(HY-10569) [1]. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .
Siponimod-d11 is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P1 and S1P5 over S1P2, S1P3, and S1P4, with EC50s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research [1] .
Sphingosine-1-phosphate-d7 is the deuterium labeled Sphingosine-1-phosphate. Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca2+ as an extracellular ligand for G protein-coupled receptors[1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids[2].
HSPD1; HSP60; 60 kDa heat shock protein; mitochondrial; 60 kDa chaperonin; Chaperonin 60; CPN60; Heat shock protein 60; HSP-60; Hsp60; HuCHA60; Mitochondrial matrix protein P1; P60 lymphocyte protein
WB, ICC/IF, IP
Human, Mouse, Rat
Hsp60 Antibody (YA730) is a non-conjugated and Mouse origined monoclonal antibody about 61 kDa, targeting to Hsp60 (6C8). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.
Caspase-12 Antibody is an unconjugated, approximately 46 kDa, rabbit-derived, anti-Caspase-12 polyclonal antibody. Caspase-12 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, background without labeling.
XRCC6; G22P1; X-ray repair cross-complementing protein 6; 5'-deoxyribose-5-phosphate lyase Ku70; 5'-dRP lyase Ku70; 70 kDa subunit of Ku antigen; ATP-dependent DNA helicase 2 subunit 1; ATP-dependent DNA helicase II 70 kDa subunit; CTC box-
WB, IHC-F, IHC-P, ICC/IF
Human
Ku70 Antibody (YA319) is a non-conjugated and Rabbit origined monoclonal antibody about 70 kDa, targeting to Ku70. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human.
Inquiry Online
Your information is safe with us. * Required Fields.
